Nuclear medicine's growing role in cardiac amyloidosis highlighted in EJNMMI collection

Nuclear medicine—including SPECT/CT, novel amyloid PET tracers, and AI—is shifting from conventional imaging toward integrated, comprehensive assessment of cardiac amyloidosis, enabling better disease characterization, risk stratification, and treatment monitoring.

• Novel amyloid PET tracers and improved SPECT/CT accuracy are advancing diagnostic capabilities.
• Multimodality imaging and systemic burden assessment now extend beyond the left ventricle.
• Longitudinal monitoring, pre-symptomatic detection, and AI applications are emerging areas of interest.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.